Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2023 07:30 ET | Source: Incannex Healthcare

Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU

MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...
October 11, 2022 08:00 ET | Source: Incannex Healthcare

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

MELBOURNE, Australia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique...
August 12, 2020 08:37 ET | Source: Equillium

Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights

LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
August 10, 2020 16:07 ET | Source: Equillium

Equillium Announces Positive Interim Data with Itolizumab in Acute GVHD Study

Complete response observed in five of seven patients in first two dose cohorts COVID-19 Pre-IND meeting request and briefing package submitted to the FDA LA JOLLA, Calif., Aug. 10, 2020 (GLOBE...
January 08, 2020 08:00 ET | Source: OWP Pharmaceuticals

OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder

NAPERVILLE, Ill., Jan. 08, 2020 (GLOBE NEWSWIRE) -- OWP Pharmaceuticals, Inc., a privately-held, commercial-stage neuroscience specialty pharmaceutical company, dedicated to developing and...
March 26, 2019 07:25 ET | Source: Cure Pharmaceutical Holding Corp.

CURE Pharmaceutical Announces Completion of FDA Pre-IND Review and Clinical Trial Plans for CUREfilm Blue™ for Erectile Dysfunction

OXNARD, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has successfully completed a pre-IND...
September 17, 2018 10:43 ET | Source: BioStem Technologies, Inc.

Nesvik Pharmaceuticals, Inc., a Subsidiary of BioStem Technologies, Inc., Announces Engagement of The Gnomon Group for Pre-Investigational New Drug Application Strategy

Pompano Beach, FL, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Nesvik Pharmaceuticals, Inc., a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), focused on...
August 14, 2017 13:56 ET | Source: Qu Biologics

Positive feedback from FDA reviewers in response to Pre-IND meeting package

VANCOUVER, British Columbia, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...